市場調査レポート

商品コード

1566205

勃起不全薬の市場規模、シェア、成長分析、タイプ別、投与経路別、地域別 - 産業予測、2024年～2031年

Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Type (Viagra, Cialis), By Route of Administration (Oral Mode of Administration, Injectable Mode of Administration), By Region - Industry Forecast 2024-2031

出版日: 2024年10月03日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

勃起不全薬の世界市場規模は、2022年に24億米ドルと評価され、2023年の26億2,000万米ドルから2031年には53億米ドルに成長し、予測期間中（2024年～2031年）のCAGRは9.20％で成長する見通しです。

勃起不全薬の世界市場は、相互に関連するいくつかの要因によって著しい成長を遂げています。肥満、心血管疾患、糖尿病、高血圧などの生活習慣病の流行に加え、座りがちなライフスタイルの増加が、これらの医薬品に対する需要の高まりにつながっています。さらに、老年人口の増加は、勃起不全に関する患者の意識の高まりに支えられ、効果的な治療オプションの必要性を高めています。新興国市場における政府の取り組みや公衆衛生キャンペーンは、市場拡大をさらに後押ししています。代替ジェネリック医薬品の存在とそれに伴うライフスタイルのストレスも、市場のダイナミクスを高めています。さらに、勃起不全を経験する男性の数が増加していることと、主要医薬品の特許が失効していることが、市場情勢に有利であることを証明しています。革新的な治療に焦点を当てた臨床試験とともに、研究開発への投資が力強い成長機会を生み出しています。しかし市場は、患者の服薬アドヒアランスの低下、偽造薬の蔓延、進行を妨げる潜在的な副作用といった課題に直面しています。市場が発展していく中で、利害関係者が複雑な勃起不全薬市場を効果的に運営していくためには、成長促進要因を活用しながらこれらのハードルに対処していくことが極めて重要になるであろう。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）

Product Code: SQMIG35I2259

Global Erectile Dysfunction Drugs Market size was valued at USD 2.4 billion in 2022 and is poised to grow from USD 2.62 billion in 2023 to USD 5.3 billion by 2031, growing at a CAGR of 9.20% during the forecast period (2024-2031).

The global market for erectile dysfunction drugs is witnessing significant growth driven by several interconnected factors. The rise in sedentary lifestyles, alongside the prevalence of lifestyle-related conditions such as obesity, cardiovascular diseases, diabetes, and hypertension, is leading to a higher demand for these medications. Additionally, the growing geriatric population is amplifying the need for effective treatment options, supported by increased patient awareness around erectile dysfunction. Government initiatives and public health campaigns in developing regions are further propelling market expansion. The presence of generic drug alternatives and associated lifestyle stresses are enhancing market dynamics as well. Furthermore, an increasing number of men experiencing erectile dysfunction, coupled with the expiration of patents for major drugs, is proving advantageous for the market landscape. Investment in research and development, along with clinical trials focusing on innovative treatments, is creating robust growth opportunities. However, the market faces challenges such as poor patient adherence, the prevalence of counterfeit medications, and potential adverse effects that may impede progress. As the market evolves, addressing these hurdles while capitalizing on growth drivers will be crucial for stakeholders to navigate the complexities of the erectile dysfunction drug market effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Drugs Market Segmental Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Erectile Dysfunction Drugs Market

The escalating prevalence of erectile dysfunction (ED) worldwide significantly propels the Global Erectile Dysfunction Drugs market, driven by a confluence of factors including sedentary lifestyles, obesity, and age-related changes. Chronic health conditions such as diabetes and cardiovascular diseases further exacerbate this issue, leading to a higher demand for effective treatment options. As societal awareness surrounding men's health increases and stigma surrounding ED diminishes, more individuals are seeking medical interventions. This trend is further supported by ongoing innovations in pharmaceutical therapies, bolstering the market's growth as a rising number of patients turn to prescribed medications and over-the-counter solutions to enhance their sexual health and overall quality of life.

Restraints in the Global Erectile Dysfunction Drugs Market

One significant market restraint for the global erectile dysfunction drugs market is the rigorous regulatory landscape governing drug development and approval. The process involves extensive clinical trials and stringent post-marketing surveillance requirements, which are both time-consuming and costly for manufacturers. These regulatory hurdles can delay product launches and increase the overall investment needed for bringing new drugs to market. Consequently, the complexity and duration of the approval process may deter potential entrants and limit innovation within the sector, ultimately constraining market growth and reducing the availability of novel treatment options for consumers seeking effective erectile dysfunction solutions.

Market Trends of the Global Erectile Dysfunction Drugs Market

The Global Erectile Dysfunction Drugs market is experiencing a notable shift towards non-oral administration routes, driven by an evolving consumer preference for treatment options that enhance convenience and immediacy. As traditional oral medications, particularly PDE5 inhibitors, continue to dominate the landscape, there is a marked rise in interest for alternative methods such as topical creams, injections, and transdermal patches. These innovative delivery systems provide localized treatment, potentially reducing systemic side effects and improving efficacy. This trend reflects a broader movement towards personalized medicine, catering to diverse patient needs and preferences, thereby fostering growth opportunities within the market.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition

Erectile Dysfunction Drugs Market by Product

Market Overview
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

Market Overview
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

勃起不全薬の市場規模、シェア、成長分析、タイプ別、投与経路別、地域別 - 産業予測、2024年～2031年

Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Type (Viagra, Cialis), By Route of Administration (Oral Mode of Administration, Injectable Mode of Administration), By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

勃起不全薬市場：製品別

勃起不全薬市場：投与経路別

勃起不全薬市場規模：地域別